Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amneal Pharmaceuticals (AMRX)

Amneal Q4 revenue rises 11% to $814 million; 2026 guidance calls for $3.05-$3.15 billion

Positive Impact 3 of 5 earnings Written later

Amneal Pharmaceuticals reported fourth-quarter 2025 net revenue of $814 million, up 11% from a year earlier, and GAAP net income attributable to the company of $35 million, compared with a loss of $31 million in the fourth quarter of 2024. For the full year, revenue rose 8% to $3.02 billion and adjusted diluted EPS was $0.83, and the company gave 2026 guidance of $3.05 billion to $3.15 billion in net revenue and $0.93 to $1.03 in adjusted diluted EPS, which is above 2025 results.

Key points

  • Q4 2025 net revenue was $814 million, up 11%, with Specialty up 38% and Affordable Medicines down 1%
  • Q4 2025 GAAP diluted EPS was $0.11 versus a loss of $0.10 a year earlier; adjusted diluted EPS was $0.21 versus $0.12
  • Full year 2025 net revenue was $3.02 billion and adjusted EBITDA was $688 million, up 10%
  • 2026 guidance: net revenue of $3.05 billion to $3.15 billion, adjusted EBITDA of $720 million to $760 million, adjusted diluted EPS of $0.93 to $1.03

The filing

CompanyAmneal Pharmaceuticals (AMRX)
Form8-K, current report
Filed with the SECFeb 27, 2026, 6:16 AM ET
Accession number0001723128-26-000008

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:59 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 27, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.